Why Is Pancreatic Cancer So Difficult to Treat — and Where Is the Hope

 

Why Is Pancreatic Cancer So Difficult to Treat — and Where Is the Hope?

Over the past several decades, advances in medicine, surgery, targeted therapy, and immunotherapy have dramatically improved survival rates for many cancers. Yet pancreatic cancer remains one of the deadliest malignancies.

Despite years of research, the prognosis for pancreatic cancer patients is still poor compared with many other tumor types. In the United States, pancreatic cancer consistently ranks among the leading causes of cancer-related death, even though it is not among the most common cancers.

Why has pancreatic cancer been so difficult to defeat? And where does the hope for future breakthroughs lie?

Scientists generally believe that three major biological challenges are responsible:

1. Pancreatic cancer is extremely difficult to detect early
2. There has long been a lack of effective targeted therapies
3. The tumor microenvironment forms a powerful protective barrier

At the same time, these challenges also point directly toward the most promising directions for future research.

1. The Biggest Problem: Pancreatic Cancer Is Difficult to Detect Early

For almost all cancers, early detection is critical. Tumors discovered at an early stage are often easier to treat and may even be curable with surgery or localized therapy alone.

Pancreatic cancer is very different. In its early stages, pancreatic cancer often causes no obvious symptoms. The pancreas is located deep inside the abdomen, making tumors difficult to detect during routine examination. In addition, there is currently no simple, inexpensive, and highly effective screening test for the general population.

As a result, many patients are diagnosed only after the cancer has already spread beyond the pancreas.

Researchers are actively searching for simpler screening strategies, including blood-based biomarkers, circulating tumor DNA (ctDNA), metabolite profiling, and AI-assisted imaging analysis.

2. The Second Challenge: A Long-Standing Lack of Effective Targeted Drugs

More than 90% of pancreatic cancers contain mutations in the KRAS oncogene, making KRAS one of the defining drivers of this disease.

For decades, KRAS was considered one of the most difficult targets in cancer biology. However, recent breakthroughs led to the development of KRAS inhibitors such as sotorasib and adagrasib, demonstrating that KRAS can indeed be targeted.

Another important advance involves PARP inhibitors. A subset of pancreatic cancer patients carry inherited BRCA1 or BRCA2 mutations, making them sensitive to PARP inhibition. Clinical studies showed that olaparib significantly prolonged progression-free survival in patients with BRCA-mutated metastatic pancreatic cancer.

3. The Tumor Microenvironment: A Protective Fortress

Pancreatic tumors are surrounded by an unusually dense stromal barrier composed of fibroblasts, immune cells, extracellular matrix proteins, hyaluronic acid, and various signaling molecules.

This dense microenvironment acts like a protective fortress that blocks chemotherapy drugs, targeted therapies, and immune cells from effectively reaching tumor cells.

Researchers have explored multiple approaches to weaken or remodel the tumor stroma, including hyaluronidase enzymes such as PEGPH20 and therapies targeting fibroblasts, cytokine signaling, and immune suppression pathways.

Reasons for Hope

Although pancreatic cancer remains extremely challenging, important progress is being made. Researchers now have a much deeper understanding of the genetic drivers of pancreatic cancer, mechanisms of drug resistance, tumor-stroma interactions, and immune suppression within tumors.

Promising areas include:
• Early detection blood tests
• KRAS-targeted therapies
• Precision medicine approaches
• Combination immunotherapy strategies
• Tumor microenvironment modulation
• AI-assisted diagnosis and treatment selection

The ultimate goal is not only to extend survival, but eventually to transform pancreatic cancer into a manageable — and perhaps one day preventable or curable — disease.

Selected References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2024. CA Cancer J Clin. 2024.
2. Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020.
3. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019.